| EFV {CICI} | R Documentation |
Pharmacoepidemiological HIV treatment data
Description
A hypothetical, simulated dataset which is line with the data-generating process of Schomaker et al. (2023) and inspired by the data of Bienczak et al. (2017); see references below.
Usage
data(EFV)
Format
A data frame with 5000 observations on the following variables:
sexThe patient's sex
metabolicMetabolism status (slow, intermediate, extensive) related to the single nucleotide polymorphisms in the CYP2B6 gene, which is relevant for metabolizing evafirenz and directly affects its concentration in the body.
log_agelog(age) at baseline
NRTINucleoside reverse transcriptase inhibitor (NRTI) component of HIV treatment, i.e. abacavir, stavudine or zidovudine.
weight.0log(weight) at time 0 (baseline)
efv.0Efavirenz concentration at time 0 (baseline)
VL.0Elevated viral load (viral failure) at time 0 (baseline)
adherence.1Adherence at time 1 (if 0, then signs of non-adherence)
weight.1log(weight) at time 1
efv.1Efavirenz concentration at time 1
VL.1Elevated viral load (viral failure) at time 1
adherence.2Adherence at time 2 (if 0, then signs of non-adherence)
weight.2log(weight) at time 2
efv.2Efavirenz concentration at time 2
VL.2Elevated viral load (viral failure) at time 2
adherence.3Adherence at time 3 (if 0, then signs of non-adherence)
weight.3log(weight) at time 3
efv.3Efavirenz concentration at time 3
VL.3Elevated viral load (viral failure) at time 3
adherence.4Adherence at time 4 (if 0, then signs of non-adherence)
weight.4log(weight) at time 4
efv.4Efavirenz concentration at time 4
VL.4Elevated viral load (viral failure) at time 4
References
Schomaker M, McIlleron H, Denti P, Diaz I. (2023) Causal Inference for Continuous Multiple Time Point Interventions, ArXiv e-prints: https://arxiv.org/abs/2305.06645.
Bienczak et al. (2017) Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets, AIDS, 31:905-915
Examples
data(EFV)
str(EFV)